Canaccord Genuity Mintains a 'Buy' on Dendreon (DNDN); Provenge Facility Approval Reduces Production Expansion Risk
Tweet Send to a Friend
Canaccord Genuity maintains a 'Buy' on Dendreon (NASDAQ: DNDN), PT $65.
Canaccord analyst says, "We reiterate our rating on DNDN ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We reiterate our rating on DNDN ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
